Treatment with Radiopharmaceuticals and Radionuclides in Breast Cancer: Current Options

Radiopharmaceutical therapy (RPT) is an effective and safe treatment for many types of cancer. RPT acts by binding radioactive atoms to tumor-associated antigens, monoclonal antibodies, nanoparticles, peptides, and small molecules. These treatments ensure that a concentrated dose is delivered to the targeted tumor tissue while preserving the normal tissues surrounding the tumor. Given these features, RPT is superior to traditional methods. This review article aimed to performa comprehensive review and evaluation of the potential of radionuclides and radiopharmaceuticals used in breast cancer treatment in preclinical studies conducted in the last five years

Radiopharmaceuticals developed for Zr-89-Immuno-PET

The development of molecular imaging agents used for imaging of cancer tissue is of great importance for the early detection of cancer. Positron emission tomography (PET) radiopharmaceuticals consists of a positron-emitting radionuclide and a molecularstructure. Zr-89-labeled monoclonal antibodies (mAbs), peptides, nanoparticles, proteins, and other compounds are called Zr-89-Immuno-PET and are used in cancer tissue imaging. This review provides a general overview of the potential of molecules labeled with Zr-89 radionuclide, which is chosen due to its long half-life, in preclinical and clinical studies. In light of these studies, radiopharmaceuticals created using nanoparticles have greater potential than those using antibodies

Design of Tc-99m-DTPA-CLP and Preliminary Evaluation in Rats

WOS: 000331795800013PubMed ID: 24148110Radiopharmaceuticals are localized in (malignant) tumor tissues by different mechanisms. One of these mechanisms, gelatinase enzyme activity, is associated with poor prognosis in cancer patients and potential targets for tumor imaging. There are some gelatinases to be associated with metastatic potential for tumor imaging to possibly predict metastases. In this study, a cyclic decapeptide conjugate, DTPA-CLP (DTPA-Cys-Leu-Pro-Gly-His-Trp-Gly-Phe-Pro-Ser-Cys), was selected as a peptide conjugate because of its selective inhibitory activity toward gelatinases. Peptide-conjugated DTPA-CLP was labeled with Tc-99m with a radiolabeling efficiency of 97.0 +/- 2.8%. After determining optimization conditions for radiolabeling, a biodistribution study of radiolabeled peptide in albino Wistar rats was performed. According to biodistribution data, Tc-99m-DTPA-CLP showed high uptake in the lung, liver, uterus, and spleen. These results show that Tc-99m-DTPA-CLP may be used for the imaging of gelatinase activity in metastatic tumors.Department of Scientific Projects at Ege University, Izmir, TurkeyEge University; Scientific and Technological Research Council of TurkeyTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [111S253]The authors gratefully acknowledge the financial support received from the Department of Scientific Projects at Ege University, Izmir, Turkey, and the Scientific and Technological Research Council of Turkey, Scientific Project (111S253)

An investigation on some of the tumor treatment cases using x-rays and electron beams

In this work, we discussed some of the applications which X-rays and electron beam used in radiotherapy for tumor treatments. This study has been performed at Radiation Oncology Department, Medicine Faculty in Gaziosmanpasa University by using the VARIAN CLINICA DHX linear accelerator which is operated in the range of 6 MeV - 15 MeV. Processes for the treatments that X-rays used for pancreas, bladder and prostate tumors and the processes that the electron beam used for some of the derm tumors are studied. Effects of X-rays and electron beams to treatments process are examined and the obtained results are presented comparatively